405 related articles for article (PubMed ID: 12761107)
1. Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutants and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model.
Monreal D; Grilló MJ; González D; Marín CM; De Miguel MJ; López-Goñi I; Blasco JM; Cloeckaert A; Moriyón I
Infect Immun; 2003 Jun; 71(6):3261-71. PubMed ID: 12761107
[TBL] [Abstract][Full Text] [Related]
2. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants.
Grilló MJ; Manterola L; de Miguel MJ; Muñoz PM; Blasco JM; Moriyón I; López-Goñi I
Vaccine; 2006 Apr; 24(15):2910-6. PubMed ID: 16439039
[TBL] [Abstract][Full Text] [Related]
3. Transposon-derived Brucella abortus rough mutants are attenuated and exhibit reduced intracellular survival.
Allen CA; Adams LG; Ficht TA
Infect Immun; 1998 Mar; 66(3):1008-16. PubMed ID: 9488389
[TBL] [Abstract][Full Text] [Related]
4. Intermediate rough Brucella abortus S19Δper mutant is DIVA enable, safe to pregnant guinea pigs and confers protection to mice.
Lalsiamthara J; Gogia N; Goswami TK; Singh RK; Chaudhuri P
Vaccine; 2015 May; 33(22):2577-83. PubMed ID: 25869887
[TBL] [Abstract][Full Text] [Related]
5. Rough vaccines in animal brucellosis: structural and genetic basis and present status.
Moriyón I; Grilló MJ; Monreal D; González D; Marín C; López-Goñi I; Mainar-Jaime RC; Moreno E; Blasco JM
Vet Res; 2004; 35(1):1-38. PubMed ID: 15099501
[TBL] [Abstract][Full Text] [Related]
6. Immunochemical identification of Brucella abortus lipopolysaccharide epitopes.
Rojas N; Freer E; Weintraub A; Ramirez M; Lind S; Moreno E
Clin Diagn Lab Immunol; 1994 Mar; 1(2):206-13. PubMed ID: 7496947
[TBL] [Abstract][Full Text] [Related]
7. Booster vaccination with safe, modified, live-attenuated mutants of Brucella abortus strain RB51 vaccine confers protective immunity against virulent strains of B. abortus and Brucella canis in BALB/c mice.
Truong QL; Cho Y; Kim K; Park BK; Hahn TW
Microbiology (Reading); 2015 Nov; 161(11):2137-48. PubMed ID: 26341622
[TBL] [Abstract][Full Text] [Related]
8. In vivo differences in the virulence, pathogenicity, and induced protective immunity of wboA mutants from genetically different parent Brucella spp.
Wang Z; Niu J; Wang S; Lv Y; Wu Q
Clin Vaccine Immunol; 2013 Feb; 20(2):174-80. PubMed ID: 23239800
[TBL] [Abstract][Full Text] [Related]
9. Lipopolysaccharide as a target for brucellosis vaccine design.
Conde-Álvarez R; Arce-Gorvel V; Gil-Ramírez Y; Iriarte M; Grilló MJ; Gorvel JP; Moriyón I
Microb Pathog; 2013 May; 58():29-34. PubMed ID: 23219811
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Brucella putative glycosyltransferase WbkA in B. abortus RB51 leads to production of exopolysaccharide.
Dabral N; Jain-Gupta N; Seleem MN; Sriranganathan N; Vemulapalli R
Front Cell Infect Microbiol; 2015; 5():54. PubMed ID: 26157707
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of wbkF gene in Brucella abortus RB51WboA leads to increased O-polysaccharide expression and enhanced vaccine efficacy against B. abortus 2308, B. melitensis 16M, and B. suis 1330 in a murine brucellosis model.
Dabral N; Burcham GN; Jain-Gupta N; Sriranganathan N; Vemulapalli R
PLoS One; 2019; 14(3):e0213587. PubMed ID: 30856219
[TBL] [Abstract][Full Text] [Related]
12. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.
Vemulapalli R; Contreras A; Sanakkayala N; Sriranganathan N; Boyle SM; Schurig GG
Vet Microbiol; 2004 Sep; 102(3-4):237-45. PubMed ID: 15327798
[TBL] [Abstract][Full Text] [Related]
13. Complementation of Brucella abortus RB51 with a functional wboA gene results in O-antigen synthesis and enhanced vaccine efficacy but no change in rough phenotype and attenuation.
Vemulapalli R; He Y; Buccolo LS; Boyle SM; Sriranganathan N; Schurig GG
Infect Immun; 2000 Jul; 68(7):3927-32. PubMed ID: 10858205
[TBL] [Abstract][Full Text] [Related]
14. Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export.
González D; Grilló MJ; De Miguel MJ; Ali T; Arce-Gorvel V; Delrue RM; Conde-Alvarez R; Muñoz P; López-Goñi I; Iriarte M; Marín CM; Weintraub A; Widmalm G; Zygmunt M; Letesson JJ; Gorvel JP; Blasco JM; Moriyón I
PLoS One; 2008 Jul; 3(7):e2760. PubMed ID: 18648644
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice.
Winter AJ; Rowe GE; Duncan JR; Eis MJ; Widom J; Ganem B; Morein B
Infect Immun; 1988 Nov; 56(11):2808-17. PubMed ID: 2844673
[TBL] [Abstract][Full Text] [Related]
16. Brucella abortusΔcydCΔcydD and ΔcydCΔpurD double-mutants are highly attenuated and confer long-term protective immunity against virulent Brucella abortus.
Truong QL; Cho Y; Park S; Kim K; Hahn TW
Vaccine; 2016 Jan; 34(2):237-244. PubMed ID: 26616550
[TBL] [Abstract][Full Text] [Related]
17. Mutants in the lipopolysaccharide of Brucella ovis are attenuated and protect against B. ovis infection in mice.
Soler-Lloréns P; Gil-Ramírez Y; Zabalza-Baranguá A; Iriarte M; Conde-Álvarez R; Zúñiga-Ripa A; San Román B; Zygmunt MS; Vizcaíno N; Cloeckaert A; Grilló MJ; Moriyón I; López-Goñi I
Vet Res; 2014 Jul; 45(1):72. PubMed ID: 25029920
[TBL] [Abstract][Full Text] [Related]
18. Non-infectious outer membrane vesicles derived from Brucella abortus S19Δper as an alternative acellular vaccine protects mice against virulent challenge.
Solanki KS; Varshney R; Qureshi S; Thomas P; Singh R; Agrawal A; Chaudhuri P
Int Immunopharmacol; 2021 Jan; 90():107148. PubMed ID: 33189614
[TBL] [Abstract][Full Text] [Related]
19. Protective role of antibodies induced by Brucella melitensis B115 against B. melitensis and Brucella abortus infections in mice.
Adone R; Francia M; Pistoia C; Petrucci P; Pesciaroli M; Pasquali P
Vaccine; 2012 Jun; 30(27):3992-5. PubMed ID: 22521283
[TBL] [Abstract][Full Text] [Related]
20. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
Winter AJ; Schurig GG; Boyle SM; Sriranganathan N; Bevins JS; Enright FM; Elzer PH; Kopec JD
Am J Vet Res; 1996 May; 57(5):677-83. PubMed ID: 8723881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
